Zoetis Inc
$ 113.83
-2.42%
29 Apr - close price
- Market Cap 49,241,199,000 USD
- Current Price $ 113.83
- High / Low $ 115.91 / 112.97
- Stock P/E 19.38
- Book Value 7.84
- EPS 6.02
- Next Earning Report 2026-05-07
- Dividend Per Share $2.00
- Dividend Yield 1.7 %
- Next Dividend Date 2026-06-02
- ROA 0.15 %
- ROE 0.66 %
- 52 Week High 169.60
- 52 Week Low 112.80
About
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Analyst Target Price
$150.29
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-02 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 1.48 | 1.7 | 1.61 | 1.48 | 1.4 | 1.58 | 1.56 | 1.38 | 1.24 | 1.36 | 1.41 | 1.31 |
| Estimated EPS | 1.4 | 1.64 | 1.52 | 1.4 | 1.36 | 1.46 | 1.49 | 1.34 | 1.32 | 1.36 | 1.32 | 1.26 |
| Surprise | 0.08 | 0.06 | 0.09 | 0.08 | 0.04 | 0.12 | 0.07 | 0.04 | -0.08 | 0 | 0.09 | 0.05 |
| Surprise Percentage | 5.7143% | 3.6585% | 5.9211% | 5.7143% | 2.9412% | 8.2192% | 4.698% | 2.9851% | -6.0606% | 0% | 6.8182% | 3.9683% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.62 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-02 | 2026-03-03 | 2025-12-02 | 2025-09-03 | 2025-06-03 | 2025-03-04 | 2024-12-03 | 2024-09-04 | 2024-06-04 | 2024-03-01 |
| Amount | $0.53 | $0.53 | $0.5 | $0.5 | $0.5 | $0.5 | $0.432 | $0.432 | $0.432 | $0.432 |
Next Dividend Records
| Dividend per share (year): | $2.00 |
| Dividend Yield | 1.7% |
| Next Dividend Date | 2026-06-02 |
| Ex-Dividend Date | 2026-04-20 |
Recent News: ZTS
2026-04-28 14:39:59
The Zacks Medical - Products industry faces challenges from tariff pressures and cost inflation but is supported by innovation and demographic trends. Phibro Animal Health, BioLife Solutions, Omeros, and Brainsway are highlighted for their differentiated strategies to counter industry headwinds. These companies are leveraging innovation, operational efficiencies, and focused execution in growth areas like biopreservation media, Deep TMS therapy, and animal health solutions.
2026-04-26 09:41:03
M&T Bank Corp significantly increased its stake in Woodward, Inc. (NASDAQ:WWD) by 135% in Q4, leading its total holdings to $6.43 million. Despite insider selling activity totaling $10.2 million, Woodward exceeded quarterly earnings and revenue estimates and provided strong FY2026 guidance, leading to analyst upgrades and elevated price targets. The company also announced an increase in its quarterly dividend.
2026-04-24 16:46:00
Stock Traders Daily's AI models indicate a mid-channel oscillation pattern for Zoetis Inc. (ZTS) with weak near-term sentiment. The analysis highlights an exceptional 28.8:1 risk-reward setup, targeting an 8.4% gain against 0.3% risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis to manage different risk profiles.
2026-04-24 11:39:00
ImmuCell (NASDAQ: ICCC) has outlined its 2026 strategy, equity plan, and executive compensation in its latest proxy statement. The company is focusing on its First Defense® product line, seeking partners for Re-Tain®, and implementing governance changes including a new CEO, a majority-independent board, and a Strategy & Technology Committee. Stockholders will vote on key proposals at the June 11, 2026 annual meeting, including the approval of the 2025 Stock Option and Incentive Plan and an amendment to the charter for officer exculpation.
2026-04-24 08:08:49
This article analyzes Zoetis (ZTS), a global animal health leader, suggesting it currently trades at a discount despite strong earnings quality and dividend growth. The analysis points to a fair value of $151.00 compared to its current share price of $116.06, indicating it is undervalued due to recurring demand in both companion animal and livestock markets. Investors are encouraged to review the company's underlying data and consider potential risks like new competition.
2026-04-23 05:08:47
Bausch Health Cos (BHC) is expected to announce its Q1 2026 earnings on Wednesday, April 29th, with analysts projecting EPS of $0.667 and revenue of $2.373 billion. The company missed EPS estimates in the prior quarter but exceeded revenue expectations, and analysts forecast $4 EPS for the current and next fiscal years. Market sentiment is largely negative, with a "Reduce" consensus rating and a target price of $8.33, despite high institutional ownership led by Paulson & Co.
